Compare Ferrari NV (RACE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ferrari NV trades at $391.98 (market cap $68.73B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ferrari NV is far larger — about 9.1× Spyre Therapeutics Inc. Common Stock's market cap, and Ferrari NV pays a 1.08% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RACE | SYRE | |
|---|---|---|
Market Cap | $68.73B | $7.52B |
Volume | 283,474 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $108.92 |
52-Week Low | $314.63 | $22.18 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $70.60B | $6.52B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $387.35, down 0.49% on the day, amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $7.15B in 2025 to a projected $7.4B in 2026 and a net income margin of 22.25%. Recent earnings beats and a share buyback program highlight operational strength. Analyst consensus is bullish with a $462.75 price target, though technical indicators show near-term pressure with support at $384.
The outlook remains positive given Ferrari's premium brand and consistent profitability, but high valuation multiples (P/E 37.67) and economic sensitivity pose risks. Institutional buying and bullish analyst ratings support upside potential, yet investors should monitor competitive pressures and macroeconomic headwinds that could impact luxury demand.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
